Archives20242023202220212020201920182017201620152014201320122011 June 07, 2016First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More May 31, 2016Notification of Major Interest by Alto Invest to 4.15% Read More May 25, 2016Notification of Major Interest by Alto Invest Read More May 04, 2016PRELIMINARY RESULTS for the year ended 31 December 2015 Read More May 04, 2016Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016 Read More April 26, 2016Notification of Preliminary Results. Date: 4 May 2016 Read More March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More February 23, 2016Result of GM Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 15, 2016First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Read More February 05, 2016Placing and Subscription Raises £8.3 million Read More 123
March 10, 2016First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Read More
March 01, 2016Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Read More
